Mara L. Becker, MD, MSCE, discusses how important it is to effectively treat juvenile idiopathic arthritis at an early stage to improve long-term outcomes in adulthood.
EU Approves Tofacitinib Citrate for 2 Pediatric Conditions
The European Commission approved tofacitinib citrate to treat two pediatric conditions, as well as a prolonged-release version of the medication designed to treat adults with active PsA.
Treatment Factors to Consider in Patients with JIA
Weighing treatment options and adjusting them to meet the needs of patients with JIA is a complicated process. Experts discussed factors influencing treatment options, optimizing treatment doses and possibilities for treatment withdrawal for these patients.
Manifestations of JIA: JIA-Associated Uveitis, sJIA & Lung Involvement in sJIA
JIA can manifest in a variety of ways. Experts discuss the implications of uveitis, systemic disease and lung involvement in sJIA.
2 Pediatric Indications Sought for Golimumab
The FDA is reviewing supplemental Biologics License Applications for golimumab to treat polyarticular JIA and juvenile PsA…
Local Depletion of Resident Memory T Cells May Reduce Site-Specific Joint Flares
A study found resident memory T cells may mediate inflammatory arthritis and trigger flares in specific joints, suggesting local depletion of these cells could be a therapeutic strategy…
JIA & the Temporomandibular Joint: Diagnostic Challenges & Treatment Options
Juvenile idiopathic arthritis (JIA) can affect all joints, including the temporomandibular joints (TMJs). For a long time, the TMJ was a “forgotten” joint in pediatric rheumatology, although Sir Frederick Still did comment on a small mandible in his first case series on juvenile arthritis in 1897. In recent years, more attention has been given to…
No Evidence to Support Biologic Switching Guidelines for JIA
NEW YORK (Reuters Health)—For young people with juvenile idiopathic arthritis (JIA) who don’t achieve disease control, switching to a different class of biologic is unlikely to be beneficial, researchers say. The observational study yielded no evidence to support or refute the 2015 National Health Service England guidelines, which recommend switching most patients to a second…
Pediatric Cases Require Special Considerations & Aggressive Treatment Plans
ATLANTA—Managing pediatric patients with rheumatic disease involves special considerations, such as developmental concerns and physiological traits that may affect dosing of medications, according to two experts. During a session at the 2019 ACR/ARP Annual Meeting, Courtney Kremer, ARNP, a pediatric nurse practitioner at the University of Iowa Stead Family Children’s Hospital, Iowa City, and Jessica…
A More Complicated Pregnancy: Inflammatory Arthritis Increases the Risk for Adverse Outcomes
Pregnant women with inflammatory arthritis may have an increased risk for preterm delivery. New research examined the risk of preterm delivery and other pregnancy complications in women with RA and JIA vs. healthy controls…